Últimas noticias sobre Beyond Air (NASDAQ:XAIR) Bolsa

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Inc

Texas Capital Securities analyst Alex Rygiel initiates coverage on Century Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCS#NYSE">CCS</a>) with a Buy rating and announces Price Target of $68.

News

Price Target

Initiation

Analyst Ratings

Texas Capital Securities Initiates Coverage On Century Communities with Buy Rating, Announces Price Target of $68

After months of cautious positioning and defensive sector leadership, investor sentiment appears to be shifting decisively toward risk-on assets. Several growth-oriented and <a href="https://www.benzinga.com/etfs">thematic ETFs</a> notched fresh 52-week highs on Monday, reflecting renewed enthusiasm for innovation, technology, and discretionary spending plays.
At the forefront of this momentum are the flagship ETFs from ARK Invest. The ARK Fintech Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#BATS">ARKF</a>) surged past $45, while the ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) crossed $135, both marking their highest levels in a year, according to Barchart. Cathie Wood's funds, known for their aggressive bets on disruptive technologies, have benefited from investor optimism around artificial intelligence, blockchain adoption, and a potential easing of macroeconomic headwinds.
Also Read: <a href="https://www.benzinga.com/news/25/06/45959562/new-tngy-etf-offers-flexible-income-focused-exposure-to-us-energy-market">New TNGY ETF Offers Flexible, Income-Focused Exposure To US Energy Market</a>
Joining the rally is the Alger AI Enablers &amp; Adopters ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALAI#NYSE">ALAI</a>), which climbed over 1.2% to a new high of $29.36. The fund provides exposure to companies positioned to benefit from the widespread adoption of artificial intelligence, a theme that has captured investor imagination since the generative AI boom took hold last year.
Meanwhile, the Roundhill Sports Betting &amp; iGaming ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BETZ#NYSE">BETZ</a>) also hit a new milestone, gaining 2.6% on the day. With names like DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) and Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) in its portfolio, BETZ represents a high-risk, high-reward corner of the market tied closely to consumer discretionary spending and regulatory developments.
Even broader allocation strategies are showing signs of risk appetite. The iShares Core Aggressive Allocation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOA#NYSE">AOA</a>), which holds a mix of U.S. and international equities tilted toward growth, rose 0.78% to a 52-week high, indicating that investors are not only chasing niche themes but also expressing broader confidence in equity markets.
<h2 class="wp-block-heading">A Broader Shift Underway?</h2>
Market analysts attribute the surge in growth-themed ETFs to a confluence of factors: resilient economic data, moderating inflation, expectations of Federal Reserve rate cuts later this year, and strong earnings performance from tech giants.
The rally in these ETFs reflects a growing consensus that the U.S. economy might achieve a soft landing. When macro fear subsides, investors naturally rotate back into higher-growth, more volatile assets.
ARKW and ARKF in particular have become proxies for investor sentiment around next-generation tech, including blockchain, digital wallets, and AI. Despite past criticism over their high volatility, the funds have rallied sharply in 2025, with ARKW up over 23% year to date.
BETZ's strength, meanwhile, suggests discretionary themes are gaining favor again, an encouraging sign for sectors that depend on consumer confidence and disposable income. While not without regulatory risk, the legalization trend in online sports betting across several U.S. states continues to support the fund&#8217;s growth story.
<h2 class="wp-block-heading">Is This Rally Sustainable?</h2>
It should be noted that valuation risks remain elevated, and any disappointment in earnings or macro data could quickly reverse the risk-on trend.
Still, for now, the market appears to be in full growth mode. The simultaneous rise of thematic funds like ALAI, speculative bets like BETZ, and broader growth-tilted portfolios like AOA suggest this isn't a narrow rally driven by a few mega caps but a more widespread return of risk appetite.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45958642/big-money-dumps-spy-but-history-says-dont-panic">Big Money Dumps SPY, But History Says Don&#8217;t Panic</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

The Alger ETF Trust Alger AI Enablers & Adopters ETF

ALAI

ARKF

ARKW

BETZ

DKNG

FLUT

Risk-On Revival: Growth-Themed ETFs Hit 52-Week Highs As Market Calms Down

Trading Ideas

SLRX

Salarius Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 55.2%

Texas Capital Securities analyst Alex Rygiel initiates coverage on Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) with a Buy rating and announces Price Target of $29.

LEGH

Texas Capital Securities Initiates Coverage On Legacy Housing with Buy Rating, Announces Price Target of $29

Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) has entered into a strategic partnership with Interpublic Group of Companies, Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) Acxiom business to <a href="https://www.benzinga.com/markets/tech/25/06/45944386/snowflake-acxiom-partner-to-power-secure-ai-marketing-for-brands">build and deliver an AI-powered marketing data infrastructure</a>.
Unique interactions through one-on-one conversations during Snowflake's annual conference provide an "on-the-ground view of trends that we expect to drive fundamentals for the software market over the next 12-18 months," according to JPMorgan.
The Snowflake Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">Analyst Mark Murphy</a> reiterated an Overweight rating and price target of $225.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The analyst provided these quotable quotes from Snowflake Summit 2025:
<ul class="wp-block-list">
<li>One of the system integrator (SI) contacts said about CEO Sridhar Ramaswamy, "I call Sridhar's policy GAGA – General Availability, General Availability. They're rolling out new products always, I love it."</li>
<li>Another SI contact said that some of their customers were generating returns on their AI investments in two to six months. He added that while the technology "itself is amazing," its rapid adoption is being curbed by "things like data readiness, governance, and change management."</li>
<li>"I'm positive on the federal opportunity and see a lot of potential in 2025," one of the contacts stated.</li>
<li>Another SI contact said, "Once Snowflake starts to really get used… it grows like wildfire."</li>
</ul>
SNOW Price Action: Shares of Snowflake had risen by 0.35% to $209.73 at the time of publication on Tuesday.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/06/45946624/canaan-stock-a-deep-dive-into-analyst-perspectives-8-ratings">Want AI Exposure? These 3 ETFs Offer Different Angles</a></li>
</ul>
Image: Shutterstock

Analyst Color

Reiteration

SNOW

Snowflake AI Push Gains Traction, JPMorgan Analyst Sees 'Potential'

Long-term care isn't just something to think about in your 80s. As Suze Orman points out in <a href="https://www.suzeorman.com/blog/Suze-School-for-Long-Term-Care-Insurance">her blog</a>, planning ahead — especially in your 50s or 60s — could make the difference between financial stability and burning through your retirement savings if the unexpected happens.
Here's why Orman says long-term care insurance deserves your attention now.
<h2 class="wp-block-heading">The Real Cost of Care Is Higher Than You Think</h2>
Needing <a href="https://www.benzinga.com/personal-finance/management/25/05/45707341/its-a-huge-problem-experts-urge-gen-xers-and-millennials-to-plan-for-long-term-carehttps://www.benzinga.com/personal-finance/management/25/05/45707341/its-a-huge-problem-experts-urge-gen-xers-and-millennials-to-plan-for-long-term-care">long-term care</a> might not mean living in a nursing home. In fact, less than 15% of long-term care happens in those facilities, according to Orman's blog. Most people receive care at home or in assisted living, which still comes with a hefty price tag — often between $5,000 and $8,000 per month. And in more intensive situations, monthly care can reach $25,000.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
If care lasts several years — the average is 3.8 years for men and 4.7 years for women — those costs can easily add up to hundreds of thousands of dollars. Alzheimer's, strokes, and other chronic conditions can push that timeline even longer.
Medicare only helps in the first three months after a hospitalization. After that, you're on your own — unless you have long-term care insurance, or you qualify for Medicaid by spending down nearly all your assets.
<h2 class="wp-block-heading">How Long-Term Care Insurance Works</h2>
<a href="https://www.benzinga.com/personal-finance/management/25/06/45930717/what-if-something-happens-to-the-person-in-control-of-an-irrevocable-trust-suze-orman-weighs-in">Orman</a> explains that LTC insurance kicks in when you need help with at least two of six basic daily activities — such as bathing or eating — for 90 days or more, or if you have a serious cognitive impairment.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
There are two main types of policies she lists:
<ol class="wp-block-list">
<li>Traditional LTC Insurance: This works much like health insurance — you pay a premium, and if you never need care, the money helps cover others' claims. Premiums can increase over time, unless you purchase a plan with guaranteed pricing. These plans may offer inflation protection and can be more affordable if you buy early.</li>
<li>Hybrid or Linked-Benefit Policies: These combine life insurance or annuities with long-term care coverage. If you never need care, your family still receives a death benefit. Premiums are usually guaranteed and require a larger upfront payment — often $100,000 or more. Some allow for flexible payments over time.</li>
</ol>
Several <a href="https://www.benzinga.com/money/best-hybrid-life-insurance-long-term-care-policies">hybrid plans</a> even offer 100% cash benefits, so you can choose your own caregivers, including family members.
<h2 class="wp-block-heading">What If You Can't Qualify for Insurance?</h2>
If you have health issues that prevent you from qualifying for standard LTC insurance, there are still options. Orman shares that fixed index annuities with long-term care riders may offer increased payouts if you need care later — sometimes double your monthly income for up to five years. These options typically have easier health requirements.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">Don't Count on the Government to Step In</h2>
Orman warned that while many state governments are implementing programs to assist with LTC, don't assume that it will provide everything you need. She listed Washington State as an example. They launched a public LTC program in 2023, funded by a payroll tax. But the lifetime benefit caps out at just $36,500 — less than six months of care in many places. Other states like California, New York and Minnesota are exploring similar programs, but none are expected to offer full financial protection.
<h2 class="wp-block-heading">Protecting Your Future</h2>
Orman urges individuals — especially those nearing or in retirement — to explore their options now. She emphasizes that even a modest LTC policy can make a big difference, covering part of the cost and preserving more of your <a href="https://www.benzinga.com/personal-finance/management/25/06/45825806/is-your-retirement-nest-egg-above-average-heres-what-people-have-in-their-401k-and-ira-at-each-age">retirement nest egg</a>.
As care costs rise, having a plan in place may give you and your family peace of mind — and keep your financial future intact.
Read Next:
<ul class="wp-block-list">
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

$25,000 Monthly Care Costs? Suze Orman Shows How Long-Term Care Insurance Can Protect Your Savings

Texas Capital Securities analyst Alex Rygiel initiates coverage on Beazer Homes USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) with a Buy rating and announces Price Target of $25.

Texas Capital Securities Initiates Coverage On Beazer Homes USA with Buy Rating, Announces Price Target of $25

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 19.18% on an annualized basis producing an average annual return of 33.3%. Currently, Fair Isaac has a market capitalization of $43.89 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 5 years ago, it would be worth $427.36 today based on a price of $1803.05 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750171512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FICO

Here's How Much You Would Have Made Owning Fair Isaac Stock In The Last 5 Years

Macro Economic Events

Politics

Global

Economics

General

Reuters Cites German Chancellor Merz Telling Broadcaster ARD "Expect Deal With U.S. In Tariff Dispute Before Summer's Over"

WIIM

Comstock Resources shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $34 price target.

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">myelodysplastic syndrome (HR-MDS)</a>.
MDS is a group of cancers in which the bone marrow doesn&#8217;t produce enough healthy blood cells.
The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45948002/abbvie-provides-update-on-verona-trial-for-newly-diagnosed-higher-risk-myelodysplastic-syndromes" rel="noreferrer noopener">and complete remission (CR)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.
Results from the VERONA trial will be available in a future medical congress and/or publication.
The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials.&nbsp;
These data do not impact any currently approved indications for venetoclax.
In the first quarter, AbbVie reported Venclexta&#8217;s revenues were&nbsp;$665 million, <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">up 8.3% year over year (+12.3%)</a>.
Last week, the U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie&#8217;s Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection" rel="noreferrer noopener">or with compensated cirrhosis.</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne disease affecting the liver.
<h2 class="wp-block-heading">AbbVie Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at AbbVie, an investor could make an assessment about a stock&#8217;s long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For AbbVie, the 200-day moving average sits at $188.78, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is below the current price of $189.54. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABBV stock is trading lower by 1.47% to $188.06 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45946402/incytes-experimental-therapy-shows-platelet-normalization-and-safety-in-rare-blood-cancer-trials-across-doses" target="_blank" rel="noreferrer noopener">Incyte&#8217;s Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

Health Care

Movers

ABBV

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and raises the price target from $8 to $9.

SAGE

Truist Securities Maintains Hold on Sage Therapeutics, Raises Price Target to $9

TMUS

T-Mobile shares are trading lower following a report indicating SoftBank plans to raise $4.9 billion through a share sale in the company.

Truist Securities analyst Michael Roxland maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Buy and raises the price target from $237 to $239.

Truist Securities Maintains Buy on Packaging Corp of America, Raises Price Target to $239

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $305 to $280.

Truist Securities Maintains Hold on Humana, Lowers Price Target to $280

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.16% to 42,448.43 while the NASDAQ fell 0.35% to 19,633.04. The S&amp;P 500 also fell, dropping, 0.23% to 6,019.32.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a>
Leading and Lagging Sectors Energy shares jumped by 1.4% on Tuesday.
In trading on Tuesday, health care stocks fell by 0.8%.
Top Headline
U.S. retail sales fell 0.9% month-over-month in May compared to a revised 0.1% decline in April and versus market estimates of a 0.7% fall.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares shot up 220% to $0.7219 after the company signed a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 for gastroparesis.</li>
<li>Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) got a boost, surging 160% to $0.7990 after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 135% to $16.20 after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares dropped 56% to $0.1706 after the company announced the pricing of a $4.3 million public offering of 21.5 million shares at $0.20 per share.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 43% to $5.50 after GLJ Research downgraded the stock from Hold to Sell. Keybanc analyst Sophie Karp also downgraded Sunrun from Sector Weight to Underweight.</li>
<li>Solaredge Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) was down, falling 39% to $14.62 after GLJ Research downgraded the stock from Hold to Sell. Keybanc analyst Sophie Karp downgraded the stock from Sector Weight to Underweight.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $73.30 while gold traded down 0.4% at $3,405.00.
Silver traded up 2% to $37.160 on Tuesday, while copper fell 0.7% to $4.8025.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.8%, while Spain's IBEX 35 Index dipped 1.2%. London's FTSE 100 fell 0.5%, Germany's DAX 40 declined 0.8% and France's CAC 40 fell 0.7% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.59%, Hong Kong's Hang Seng Index falling 0.34%, China's Shanghai Composite falling 0.04% and India's BSE Sensex falling 0.26%.
Economics
<ul class="wp-block-list">
<li>U.S. retail sales fell 0.9% month-over-month in May compared to a revised 0.1% decline in April and versus market estimates of a 0.7% fall.</li>
<li>U.S. import prices came in unchanged from the previous month in May, while export prices declined 0.9% month-over-month in May.</li>
<li>U.S. industrial production declined 0.2% in May, versus market estimates of a 0.1% gain.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined two points to 32 for June, recording the lowest reading since December 2022.</li>
<li>U.S. business inventories came in flat month-over-month in April following a 0.1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

ACXP

CERO

PCSA

SDST

SEDG

US Stocks Lower; Retail Sales Decline In May

Canaccord Genuity analyst Whitney Ijem downgrades Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) from Buy to Hold and lowers the price target from $39 to $13.

Downgrades

VERV

Canaccord Genuity Downgrades Verve Therapeutics to Hold, Lowers Price Target to $13

PureCycle Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) shares are trading higher by 23.1% at $14.61 Tuesday morning following a strategic announcement poised to accelerate the company&#8217;s global footprint.
Investors are reacting positively to the company&#8217;s <a href="https://www.benzinga.com/pressreleases/25/06/ac45969126/purecycle-announces-300-million-capital-raise-outlines-growth-plan-for-one-billion-pounds-of-inst">plan</a> to achieve one billion pounds of installed recycling capacity by 2030 across the United States, Europe and Asia.
What To Know: PureCycle Technologies says this plan includes a $300 million capital raise, with binding agreements executed with new and existing investors, including names like Duquesne Family Office LLC and Samlyn Capital. This capital infusion directly supports PureCycle&#8217;s growth initiatives.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/06/45973310/surgery-partners-rejects-bain-capitals-private-buyout-offer-will-remain-independent">Surgery Partners Rejects Bain Capital&#8217;s Private Buyout Offer, Will Remain Independent</a>
Adding to the positive momentum, PureCycle has <a href="https://www.benzinga.com/pressreleases/25/06/ac45969126/purecycle-announces-300-million-capital-raise-outlines-growth-plan-for-one-billion-pounds-of-inst">announced</a> a new partnership with IRPC Public Company Limited, Southeast Asia&#8217;s petrochemical leader, to construct a 130-million-pound polypropylene recycling facility in Thailand. 
This facility, leveraging IRPC&#8217;s existing infrastructure, is expected to commence construction in the latter half of 2025 and become operational by mid-2027. Further expansion includes a 130-million-pound line in Antwerp, projected for 2028, and a larger Gen 2 line in Augusta, Georgia, expected to be operational by 2029.
Key Stats: The company&#8217;s trading volume today stands at 4.5 million shares early Tuesday, significantly higher than its 100-day average volume of 2.915 million shares. Short interest in the stock remains high, with 48.812 million shares short, representing 45.47% of the float, according to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest">Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill</a>
<h2 class="wp-block-heading">How To Buy PCT Stock</h2>
By now you're likely curious about how to participate in the market for PureCycle Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, PCT has a 52-week high of $15.58 and a 52-week low of $4.50.

PureCycle Technologies (PCT) Stock Soars On $300M Raise & Global Expansion

JBLU

JetBlue shares are trading lower on a report suggesting the company will cut more flights and other costs, with break-even in 2025 is "unlikely" due to weaker travel demand.

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 15 years by 9.36% on an annualized basis producing an average annual return of 21.41%. Currently, Visa has a market capitalization of $683.84 billion. 
Buying $100 In V: If an investor had bought $100 of V stock 15 years ago, it would be worth $1,812.04 today based on a price of $356.79 for V at the time of writing.
<h3>Visa's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750170613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Press Releases

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Financing

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Comments

Beyond Air

Noticias

Últimas noticias sobre Beyond Air (NASDAQ:XAIR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL